Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Shattuck Labs Inc | STTK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.09 | 04:46:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.09 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.3301 - 11.11 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 9.09 | USD |
Shattuck Labs Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 431.55M | 47.47M | - | 1.66M | -87.3M | -1.84 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Shattuck Labs News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STTK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.86 | 10.25 | 8.71 | 9.52 | 274,697 | 0.23 | 2.60% |
| 1 Month | 8.17 | 10.25 | 8.06 | 9.19 | 268,994 | 0.92 | 11.26% |
| 3 Months | 10.01 | 11.11 | 8.06 | 9.23 | 318,184 | -0.92 | -9.19% |
| 6 Months | 1.49 | 11.11 | 1.36 | 6.30 | 967,272 | 7.60 | 510.07% |
| 1 Year | 2.83 | 11.11 | 1.3301 | 6.17 | 497,267 | 6.26 | 221.20% |
| 3 Years | 31.725 | 38.90 | 1.3301 | 8.37 | 279,878 | -22.64 | -71.35% |
| 5 Years | 18.61 | 60.5162 | 1.3301 | 11.09 | 265,374 | -9.52 | -51.16% |
Shattuck Labs Description
| Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. |
